1. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. (31st October 2013) Authors: López‐Ferrer, A.; Vilarrasa, E.; Gich, I.J.; Puig, L. Journal: British journal of dermatology Issue: Volume 169:Number 5(2013:Nov.) Page Start: 1141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Crusted (Norwegian) scabies: an under‐recognized infestation characterized by an atypical presentation and delayed diagnosis. (26th November 2014) Authors: Yélamos, O.; Mir‐Bonafé, J.F.; López‐Ferrer, A.; Garcia‐Muret, M.P.; Alegre, M.; Puig, L. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 30:Number 3(2016:Mar.) Page Start: 483 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Definition of minimal disease activity in psoriasis. (28th July 2020) Authors: Carretero, G.; Carrascosa, J.M.; Puig, L.; Sánchez‐Carazo, J.L.; López‐Ferrer, A.; Cueva, P.; Soria, C.; Rivera, R.; Belinchón, I. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 2(2021) Page Start: 422 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Long‐term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions. (13th December 2013) Authors: Spertino, J.; López‐Ferrer, A.; Vilarrasa, E.; Puig, L. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 28:Number 11(2014:Nov.) Page Start: 1514 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Real‐world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis. (1st September 2021) Authors: Iznardo, H.; Vilarrasa, E.; López‐Ferrer, A.; Puig, L. Journal: British journal of dermatology Issue: Volume 185:Number 3(2021) Page Start: 660 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Real‐world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis. (4th June 2021) Authors: Iznardo, H.; Vilarrasa, E.; López‐Ferrer, A.; Puig, L. Journal: British journal of dermatology Issue: Volume 185:Number 3(2021) Page Start: 660 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Real‐world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. (17th June 2020) Authors: del Alcázar, E.; Suárez‐Pérez, J.A.; Armesto, S.; Rivera, R.; Herrera‐Acosta, E.; Herranz, P.; Martín, I.; Montesinos, E.; Hospital, M.; Vilarrasa, E.; Ferran, M.; Ruiz‐Villaverde, R.; Sahuquillo‐Torralba, A.; Ruiz‐Genao, D.P.; Pérez‐Barrio, S.; Muñoz, C.; Llamas, M.; Valentí, F.; Mitxelena, M.J.... Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 12(2020) Page Start: 2821 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Subclinical enthesopathy of extensor digitorum tendon is highly prevalent and associated with clinical and ultrasound alterations of the adjacent fingernails in patients with psoriatic disease. (24th May 2018) Authors: Moya Alvarado, P.; Roé Crespo, E.; Muñoz‐Garza, F.Z.; López‐Ferrer, A.; Laiz Alonso, A.; Vilarrassa Rull, E.; Casademont i Pou, J.; Puig Sanz, L. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 32:Number 10(2018) Page Start: 1728 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗